BioSig Technologies, Inc. Stock

Equities

BSGM

US09073N3008

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 16:00:00 2024-04-26 EDT 5-day change 1st Jan Change
1.37 USD +5.38% Intraday chart for BioSig Technologies, Inc. -2.84% -71.16%
Sales 2024 * 100K 137K Sales 2025 * 1M 1.37M Capitalization 15.34M 20.97M
Net income 2024 * -6M -8.2M Net income 2025 * -12M -16.4M EV / Sales 2024 * 153 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 15.3 x
P/E ratio 2024 *
-1.83 x
P/E ratio 2025 *
-1.05 x
Employees 4
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.19%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.38%
1 week-2.84%
Current month+107.26%
1 month+191.49%
3 months-37.16%
6 months-72.87%
Current year-71.16%
More quotes
1 week
1.25
Extreme 1.25
1.59
1 month
0.48
Extreme 0.48
2.98
Current year
0.26
Extreme 0.2619
4.75
1 year
0.26
Extreme 0.2619
16.50
3 years
0.26
Extreme 0.2619
45.80
5 years
0.26
Extreme 0.2619
124.30
10 years
0.26
Extreme 0.2619
124.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 02-26
Chief Administrative Officer 51 09-02-23
Chief Tech/Sci/R&D Officer 74 09-02-23
Members of the board TitleAgeSince
Chief Tech/Sci/R&D Officer 74 09-02-23
Chief Executive Officer 58 02-26
More insiders
Date Price Change Volume
24-04-26 1.37 +5.38% 96,068
24-04-25 1.3 -1.52% 55,164
24-04-24 1.32 -10.81% 154,915
24-04-23 1.48 -4.82% 83,619
24-04-22 1.555 +10.28% 216,573

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm

More quotes
BioSig Technologies, Inc. is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. The Company’s product, the PURE EP Platform, a non-invasive class II device, provides real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures. Integrating with existing systems in the EP lab, PURE EP is designed to pinpoint even the complex signals to maximize procedural success and efficiency. The PURE EP System is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise from other equipment, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials. PURE EP is a signal processing platform that combines advanced hardware and software to address known challenges associated to signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-time.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.37 USD
Average target price
7.5 USD
Spread / Average Target
+447.45%
Consensus